COMPOSITION PHARMACEUTIQUE DESTINÉE À ÊTRE UTILISÉE DANS LA PRÉVENTION ET/OU LE TRAITEMENT D'UNE MALADIE QUI SE DÉVELOPPE OU PROGRESSE EN RAISON D'UNE BAISSE OU D'UNE PERTE D'ACTIVITÉ DU FACTEUR VIII DE COAGULATION SANGUINE ET/OU DU FACTEUR VIII DE COAGULATION SANGUINE ACTIVÉ
The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.